Regeneron and Sanofi report Phase I response data for cemiplimab in NSCLC

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NYSE:SNY) reported interim data from 21 evaluable patients with advanced non-small cell lung cancer (NSCLC) from the dose-escalation portion or an expansion cohort of a Phase I trial showing that cemiplimab (REGN2810, SAR439684) every two weeks led to an overall response rate (ORR) of 28.6%, including six partial responses. The duration of response exceeded eight months in five of the responders. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

The open-label, international trial is enrolling about 398 patients with advanced malignancies. Cemiplimab is a human mAb against PD-1...